SQSTM1 and breast carcinoma: After the CB-2 treatment, SQSTM1 and LC3B-II accumulated in NCI-H157 NSCLC cells and in other tumor cell types, including human breast cancer (BC) MCF-7 cells and hepatocellular carcinoma (HCC) HepG2 cells (Figure S2).